Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03749460 · ClinicalTrials.gov registry record · Phase 1
Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers
A Phase 1 study of Metastatic Malignant Neoplasm in the Bone and Metastatic Malignant Neoplasm in the Lung, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03749460 is a Phase 1 study of Metastatic Malignant Neoplasm in the Bone and Metastatic Malignant Neoplasm in the Lung that has completed, run by University of Washington. The registered enrollment target is 20 participants, below the 248-participant average among 16 other Metastatic Malignant Neoplasm in the Bone trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03749460, a Phase 1 study of Metastatic Malignant Neoplasm in the Bone and Metastatic Malignant Neoplasm in the Lung, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I/II trial studies the side effects and how well nivolumab and ipilimumab works when given together with stereotactic body radiation therapy (SBRT) in treating patients with salivary gland cancers. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving nivolumab and ipilimumab and SBRT may work better in treating patients with advanced salivary gland cancers.
Conditions Studied
Interventions
- RADIATION Stereotactic Body Radiation Therapy
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
Study Locations (1)
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-01-15 |
| Est. Completion | 2023-11-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03749460
The ClinicalTrials.gov registry entry for NCT03749460 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 248-participant average among 16 other Metastatic Malignant Neoplasm in the Bone trials with a reported enrollment target (92% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Metastatic Malignant Neoplasm in the Bone appearing as the primary indexed condition, and to 3 interventions - of which Stereotactic Body Radiation Therapy is the first listed.
NCT03749460 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT03749460 about?
NCT03749460 is a clinical study titled "Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers". This phase I/II trial studies the side effects and how well nivolumab and ipilimumab works when given together with stereotactic body radiation therapy (SBRT) in treating patients with salivary gland cancers. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the bo...
What is the current status of trial NCT03749460?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2019-01-15. Estimated completion is 2023-11-05.
What conditions does trial NCT03749460 study?
This clinical trial studies the following conditions: Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lung, Stage IV Major Salivary Gland Cancer AJCC v8, Salivary Gland Carcinoma, Stage IVA Major Salivary Gland Cancer AJCC v8.
What interventions are being tested in trial NCT03749460?
The interventions under investigation include: Stereotactic Body Radiation Therapy (RADIATION), Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03749460?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03749460 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Malignant Neoplasm in the Bone
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases
RECRUITING · Phase 1
-
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
RECRUITING · Phase 1
-
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
RECRUITING
-
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
RECRUITING · NA
-
Comparing Radiation Therapy to Usual Care for Patients With High-Risk Bone Asymptomatic Metastases, PREEMPT Trial
RECRUITING · Phase 3
-
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
RECRUITING
Explore more on PlainTrial
Metastatic Malignant Neoplasm in the Bone
All registered trials for this condition
Metastatic Malignant Neoplasm in the Lung
All registered trials for this condition
Washington
All trials with a study site in Washington
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.